Department of Biotechnology, All India Institute of Medical Sciences, New Delhi, India.
Scand J Immunol. 2013 Nov;78(5):468-77. doi: 10.1111/sji.12104.
Invariant natural killer T (iNKT) cells are glycolipid-reactive T lymphocytes that share receptors and function with natural killer (NK) cells and reportedly play a pivotal role in various immune responses. However, iNKT cells are not well characterized in patients with oral squamous cell carcinoma (OSCC). We investigated the populations and functions of circulating iNKT (CD3(+) 6B11(+) ) cells from thirty-eight patients with OSCC and twenty-eight healthy donors by flow cytometry. Circulating iNKT cells were significantly lower (P < 0.01) in patients as compared to those in healthy controls. Further, iNKT subsets revealed a marked decrease in CD4(-) CD8(-) (double negative, DN) subset with concomitant increase in CD8(+) subset in patients as compared to healthy controls (P = 0.03 and P < 0.01, respectively), whereas CD4(+) subset was similarly distributed in both groups. The functional analysis demonstrated that residual iNKT cells from patients had impaired proliferative response to α-galactosylceramide (α-GalCer)-pulsed dendritic cells (DCs) and Th2-like cytokine profile. However, in vitro activation with α-GalCer-pulsed DCs restores IFN-γ expression and enhances antitumour activity to human cancer cells lines (SCC-4, KB and MCF7). It appears that the selectively enriched iNKT subsets and modulation of their function by specific ligand/agonist may be useful for cellular therapy in patients with OSCC. Further, reduced levels of iNKT cells and its DN subset may be used as potential prognostic factors for patients with OSCC.
不变自然杀伤 T(iNKT)细胞是糖脂反应性 T 淋巴细胞,它们与自然杀伤(NK)细胞共享受体和功能,据报道在各种免疫反应中发挥关键作用。然而,iNKT 细胞在口腔鳞状细胞癌(OSCC)患者中尚未得到很好的描述。我们通过流式细胞术研究了 38 例 OSCC 患者和 28 例健康对照者循环 iNKT(CD3(+)6B11(+))细胞的群体和功能。与健康对照组相比,循环 iNKT 细胞在患者中明显降低(P < 0.01)。此外,与健康对照组相比,iNKT 亚群显示 CD4(-)CD8(-)(双阴性,DN)亚群明显减少,同时 CD8(+)亚群增加(P = 0.03 和 P < 0.01),而 CD4(+)亚群在两组中分布相似。功能分析表明,患者残留的 iNKT 细胞对α-半乳糖基神经酰胺(α-GalCer)脉冲树突状细胞(DCs)的增殖反应受损,且表现出 Th2 样细胞因子谱。然而,用α-GalCer 脉冲 DCs 体外激活可恢复 IFN-γ表达,并增强对人癌细胞系(SCC-4、KB 和 MCF7)的抗肿瘤活性。似乎选择性富集的 iNKT 亚群及其功能的调节可能对 OSCC 患者的细胞治疗有用。此外,iNKT 细胞及其 DN 亚群水平降低可作为 OSCC 患者的潜在预后因素。